The Science of Seelos

Seelos intends to become a leading biopharmaceutical company focused on neurological and psychiatric disorders, including orphan indications by:

  • Advancing SLS-002 for Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) and Post-Traumatic Stress Disorder (PTSD)
  • Collaborate with Team Sanfilippo Foundation (TSF) to advancing SLS-005 to address the needs of patients with Sanfilippo syndrome
  • Advancing SLS-006 in early stage and late stage Parkinson’s disease (PD) as a monotherapy and adjunctive therapy, respectively
  • Evaluate a peptide-based approach targeting the NACore (nonamyloid component core) in PD in a proof of concept, in-vivo delivery of SLS-007 in a PD transgenic mice model
  • Filing an IND for SLS-008 in pediatric esophagitis and another undisclosed indication
  • Forming strategic collaborations in the European Union and Asian markets
  • Acquiring synergistic assets in the central nervous system therapy space through licensing and partnerships